Schneider Eugene 4
4 · IONIS PHARMACEUTICALS INC · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Eugene Schneider Sells 5,812 Shares
What Happened
Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals (IONS), sold 5,812 shares on March 19, 2026 in an open-market/private sale. The shares were sold for a weighted-average price of $70.97, generating proceeds of approximately $412,486. This was a sale (not a purchase); sales by insiders are often routine and may be pre-planned.
Key Details
- Transaction date: 2026-03-19; Form 4 filed: 2026-03-23.
- Shares sold: 5,812; weighted-average price: $70.97; total proceeds ≈ $412,486.
- Price range reported: $70.76 to $71.375 (shares were sold in multiple transactions within this range).
- Shares owned after transaction: Not disclosed on this Form 4.
- Footnotes: (1) Sale executed pursuant to a Rule 10b5-1 trading plan adopted by Schneider on Nov 19, 2025. (2) The reported price is a weighted average; the filer will provide per-price breakdown on request.
- Filing timeliness: No late-filing flag provided in the filing data.
Context
A 10b5-1 trading plan indicates the transaction was pre-arranged and executed under a preset schedule, which can reduce the extent to which the sale reflects the insider’s current view on the stock. For retail investors, purchases often carry more direct informational weight than routine or plan-based sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-19$70.97/sh−5,812$412,486→ 63,890 total
Footnotes (2)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.76 to $71.375 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission,upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.